Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2022 Earnings Call Transcript
Operator: Thank you for standing by, and welcome to Coherus Biosciences Fourth Quarter and Fiscal Year 2022 Earnings Conference Call.
Source: insidermonkey.com
Page 3 - Coherus Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Coherus Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Coherus Bioscience Today - Breaking & Trending Today
Switching Patterns Among Diabetic Macular Edema: Regeneron's Eylea Withstands the Evolving DME Switch Landscape
/PRNewswire/ -- The patient switch territory is evolving as more agents become available. Spherix's RealWorld Dynamix™ report allows for an inside look into...
Source: prnewswire.com
Switching Patterns Among Neovascular Age-Related Macular Degeneration: Genentech's Vabysmo Rising, Regeneron's Eylea and Genentech's Off-Label Avastin Remain Strong, According to Spherix Global Insights
/PRNewswire/ -- The switch landscape represents an active segment of the market where brands have the opportunity to capture share. Spherix's RealWorld...
Source: prnewswire.com
Implications of Biosimilar Availability in the United States' Ophthalmology Markets Highlighted in New Spherix Global Insights Study
/PRNewswire/ -- Ophthalmologists saw the entry of the first biosimilars into the armamentarium in 2022 with the launch of Biogen and Samsung's Byooviz and...
Source: prnewswire.com
Implications of Biosimilar Availability in the United States' Ophthalmology Markets Highlighted in New Spherix Global Insights Study
/PRNewswire/ -- Ophthalmologists saw the entry of the first biosimilars into the armamentarium in 2022 with the launch of Biogen and Samsung's Byooviz and...
Source: prnewswire.com